Ignite Creation Date:
2025-12-24 @ 6:34 PM
Ignite Modification Date:
2025-12-29 @ 3:57 AM
Study NCT ID:
NCT00638157
Status:
TERMINATED
Last Update Posted:
2021-02-02
First Post:
2008-03-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-02-13
Start Date Type:
ACTUAL
Primary Completion Date:
2011-11-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-11-09
Completion Date Type:
ACTUAL
First Submit Date:
2008-03-12
First Submit QC Date:
None
Study First Post Date:
2008-03-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2013-03-04
Results First Submit QC Date:
None
Results First Post Date:
2013-05-22
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-15
Last Update Post Date:
2021-02-02
Last Update Post Date Type:
ACTUAL